➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
McKesson
Harvard Business School
McKinsey
Merck

Last Updated: April 11, 2021

DrugPatentWatch Database Preview

Litigation Details for In re ACTOS Antitrust Litigation (S.D.N.Y. 2013)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in In re ACTOS Antitrust Litigation
The small molecule drugs covered by the patent cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for In re ACTOS Antitrust Litigation (S.D.N.Y. 2013)

Date Filed Document No. Description Snippet Link To Document
2015-09-22 221 (“584 patent”) and 6,329,404 (“404 patent”). 'l`he 584 and 404 patents also claimed methods of using…submitted patent information for the 584 and 404 patents, describing them as drug product patents claiming…the 584 and 404 patents in the Orange Book as “drug product patents” because those patents did “not claim…brand’s patents. Any ANDA submitted must contain “an appropriate certification for each listed patent.” 21…product Where there are no applicable patents, or the patents have expired or will expire prior to the External link to document
2018-03-14 255 and 6,329,404 (the “’404 Patent”)—claim the ACTOS drug product. These patents plainly and unambiguously…its patent information that the two patents—United States Patent Nos. 5,965,584 (the “’584 Patent”) and…the ’777 Patent, the ’584 Patent, and the ’404 Patent, Takeda submitted eight other patents to the FDA…the ’584 Patent and the ’404 Patent as drug- product patents claiming ACTOS only if the patents in fact…improper patent information describing the ’584 Patent and ’404 Patent as drug product patents for ACTOS External link to document
2019-09-30 272 Memorandum & Opinion other patents—U.S. Patent Nos. 5,965,584 (the “’584 patent”) and 6,329,404 (the “’404 patent”)—which… “[p]rocess patents, patents claiming packaging, patents claiming metabolites, and patents claiming intermediates… several patents related to its diabetes medicines. The first of those patents, U.S. Patent. No. 4,687,777…hereinafter “the Patents”) as both drug product patents and method- of-use patents (and improperly so, in…describe the Patents exactly as it did—that is, as both drug product patents and method-of-use patents for the External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Baxter
Mallinckrodt
Medtronic
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.